drugset / Trial / NCT00099242

Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease

NCT00099242

Phase 3 Completed 1040 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

The goal of this research study is to evaluate the safety and efficacy of the rivastigmine transdermal patch in patients with probable Alzheimer's Disease.

Timeline

Start
2003-11
Primary completion
Completion
2006-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Rivastigmine Small molecule 9.5 mg Other

Indications